Dazoxiben hydrochloride

Dazoxiben hydrochloride (CAS No.: 74226-22-5) is a selective and orally active inhibitor of thromboxane synthase, a key enzyme in the arachidonic acid cascade responsible for the conversion of prostaglandin endoperoxides to thromboxane A2, thereby modulating platelet aggregation and prostanoid balance. This compound effectively suppresses thromboxane B2 formation in platelet-rich systems and renal tissues, while concomitantly shifting prostaglandin metabolism toward increased production of prostaglandin E2 relative to other prostanoids such as prostaglandin F2α and 6-keto-prostaglandin F1α. In vitro studies demonstrate inhibitory activity in the low micromolar range in human whole blood, with comparatively higher concentrations required to achieve similar suppression in isolated renal glomeruli, reflecting tissue-specific differences in enzyme accessibility and metabolic context. Dazoxiben hydrochloride is widely utilized in biochemical and pharmacological research to investigate thromboxane-mediated signaling pathways, platelet function, and the interplay between thromboxane and prostacyclin pathways, as well as in experimental models of vascular and renal physiology. The concentrations employed in experimental systems vary depending on assay conditions, cell types, and study objectives, making it a valuable tool compound for mechanistic studies and drug discovery efforts targeting eicosanoid biosynthesis.